Stockreport

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

Marinus Pharmaceuticals, Inc.  (MRNS) 
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.marinuspharma.com/investor-relations
PDF All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical C [Read more]